VKTX - Viking Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development19,04013,7419,000.4996,966.842
Selling General and Administrative7,1215,3294,846.7765,029.636
Non Recurring----
Others----
Total Operating Expenses26,16119,07013,847.27511,996.478
Operating Income or Loss-26,161-19,070-13,847.275-11,996.478
Income from Continuing Operations
Total Other Income/Expenses Net4,098-1,508-884.547-11,407.51
Earnings Before Interest and Taxes-26,161-19,070-13,847.275-11,996.478
Interest Expense-562-1,951-2,032.34-1,018.502
Income Before Tax-22,063-20,578-14,731.822-23,403.988
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-22,063-20,578-14,731.822-23,403.988
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-22,063-20,578-14,731.822-23,403.988
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-22,063-20,578-14,731.822-23,403.988